UK – NICE recommends Novartis’ wet AMD drug Beovu

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Novartis’ anti-VEGF treatment Beovu (brolucizumab) for routine NHS use in wet age-related degeneration (AMD) patients.

The final appraisal determination (FAD) recommendation was based on the results from Novartis’ phase III HAWK and HARRIER trials, in which Beovu met the primary endpoint.

This included demonstrating improvements in best-corrected visual acuity (BCVA) from baseline that were non-inferior to Regeneron’s Eylea (aflibercept) at week 48.

Additionally, approximately 30% of Beovu-treated patients gained at least 15 letters at week 48 and vision gain was observed as early as four weeks into the trial and sustained over the course of the study…